Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients
Alkylating agent treatment is efficient in a limited subpopulation of metastatic colorectal cancer (mCRC) patient. Improved patient selection is warranted. Dual assessment of O(6)-methylguanine-DNA-methyltransferase (immunohistochemistry + digital PCR for methylation) is proposed. Retrospectively, combined score enhanced selection of patients with expected clinical benefit from alkylating agents.